Celltrion and Pfizer’s Hospira have cemented a legal victory for their Inflectra/Remsima (infliximab-dyyb) biosimilar in the US, with a Court of Appeals affirming that the cell-culture media they use to produce the biosimilar of Janssen’s Remicade (infliximab) does not infringe the originator’s intellectual property.
In a one-page ruling, Federal Circuit judges Evan Wallach, Richard Taranto and Kara Stoll affirmed per curiam a Massachusetts district...






